Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes

被引：0
作者：
Hong-wei Gao
Chao Xie
Hai-ning Wang
Yu-jing Lin
Tian-pei Hong
机构：
[1] Peking University Third Hospital,Department of Endocrinology
来源：
Acta Pharmacologica Sinica | 2007年 / 28卷
关键词：
nateglinide; acarbose; free fatty acids; asymmetric dimethylarginine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：534 / 539
页数：5
相关论文
共 50 条
[41]   Coefficient of β-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose [J].
Göke, B ;
Lübben, G ;
Bates, PC .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2004, 112 (02) :115-117
[42]   Postmarketing Surveillance of Acarbose Treatment in Taiwanese Patients with Type 2 Diabetes Mellitus [J].
Yi-Jen Hung ;
Shi-Wen Kuo ;
Chao-Hung Wang ;
Hung-Yu Chang ;
Sheng-Hwu Hsieh ;
Harald Landen .
Clinical Drug Investigation, 2006, 26 :559-565
[43]   Study of nateglinide in Japan: Long-term treatment of patients with type 2 diabetes [J].
Hiroto Taki ;
Toshio Maki ;
Takako Iso ;
Kenji Iwamoto ;
Taiichi Kajiura .
Advances in Therapy, 2006, 23 :307-324
[44]   International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus [J].
Li, Chunlin ;
Hung, Yi-Jen ;
Qamruddin, Karim ;
Aziz, Mohamed Fahmy Abdel ;
Stein, Herbert ;
Schmidt, Birgit .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 92 (01) :57-64
[45]   Study of nateglinide in Japan: Long-term treatment of patients with type 2 diabetes [J].
Taki, H ;
Maki, T ;
Iso, T ;
Iwamoto, K ;
Kajiura, T .
ADVANCES IN THERAPY, 2006, 23 (02) :307-324
[46]   EFFECTS OF ACARBOSE AND SIGLITINE ON BLOOD GLUCOSE FLUCTUATION AND ISLET β-CELL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS [J].
Wang, R. R. ;
Lv, Z. M. ;
Dan, Y. P. ;
Chen, K. Y. ;
Zhang, C. .
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02) :365-374
[47]   Long-Term Improvement of Metabolic Control by Acarbose in Type 2 Diabetes Patients Poorly Controlled with Maximum Sulfonylurea Therapy [J].
Werner Bachmann ;
Dieter Petzinna ;
Sotirios A. Raptis ;
Thomas Wascher ;
Torsten Westermeier .
Clinical Drug Investigation, 2003, 23 :679-686
[48]   Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes [J].
Hanefeld, M ;
Haffner, SM ;
Menschikowski, M ;
Koehler, C ;
Temelkova-Kurktschiev, T ;
Wildbrett, J ;
Fischer, S .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2002, 55 (03) :221-227
[49]   Acute nateglinide administration in subjects with type 2 diabetes: Effects on postprandial metabolism, coagulation, and fibrinolysis [J].
Tentolouris, N ;
Boutati, E ;
Karambakalis, N ;
Perea, D ;
Tselepis, AD ;
Tsoukala, C ;
Kyriaki, D ;
Lourida, E ;
Anastasopoulou, I ;
Karafoullidou, A ;
Raptis, SA ;
Katsilambros, N .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2005, 15 (01) :6-12
[50]   Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes [J].
Salman, S ;
Salman, F ;
Satman, I ;
Yilmaz, Y ;
Özer, E ;
Sengül, A ;
Demirel, HÖ ;
Karsidag, K ;
Dinççag, N ;
Yilmaz, MT .
CURRENT MEDICAL RESEARCH AND OPINION, 2001, 16 (04) :296-306
12345